Gemcitabine intravesical system+intravenous cetrelimab did not improve bladder-intact event-free survival or OS for pts with MIBC who did not receive radical cystectomy.

Findings presented at the 2026 ASCO GU Symposium show that combinatorial therapies may provide new treatment options for patients with renal cell carcinoma or muscle-invasive bladder cancer.

Patients who receive durvalumab plus tremelimumab for resected RCC report worse quality of life compared to those who receive active monitoring.

Capivasertib+abiraterone was associated with more symptomatic AEs but did not impact HRQoL in patients with PTEN-deficient ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...

Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...

Disitamab vedotin has shown antitumor activity in HER2-expressing subgroups with pretreated, locally advanced unresectable or metastatic urothelial cancer.

In mCRPC patients with BRCA1/2 or ATM alterations, first-line treatment with abiraterone plus prednisone and olaparib improves OS.

Investigators evaluated the long-term neurological, neurocognitive, social, and quality of life outcomes associated with posterior fossa syndrome among survivors of medulloblastoma.

In this population-based analysis, researchers aimed to assess whether menopausal hormone therapy increases the risk of all-cause mortality.

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.